Serina presents non-immunogenic POZ-lipid data at ACS 2025 meeting

Serina Therapeutics, Inc.

Randall Moreadith, M.D., Ph.D., Chief Development Officer, presented at ACS Spring 2025 in San Diego.
Presentation titled 'A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles'.
In rats, POZ-lipid did not trigger IgM or IgG antibody response after repeat dosing.
In contrast, PEG-lipid standards elicited a strong and boosted antibody response.
Non-immunogenic POZ-lipid could enable safer LNP formulations for gene therapy and RNA medicines.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.